The magnetic properties of nanoparticle assemblies have been investigated in detail through a combination of vibrating sample magnetometry (VSM) and muon spin relaxation () techniques. Two samples with average particle sizes of 5 and 20 nm, respectively, were studied. For both samples, the VSM and results exhibit clear signatures of superparamagnetism at high temperature and magnetic blocking at low temperature. The data demonstrate that the transition from the superparamagnetic to the blocked state occurs gradually throughout the sample volume over an extended temperature range due to the finite particle size distribution of each nanoparticle batch. The transition occurs between approximately 3 and 45 K for the 5-nm nanoparticles and 150 and 300 K for the 20-nm nanoparticles. The VSM and data are further analyzed to yield estimates of microscopic magnetic parameters including the nanoparticle spin-flip activation energy , magnetic anisotropy , and intrinsic nanoparticle spin reversal attempt time . These results highlight the complementary information about magnetic nanoparticles that can be obtained by bulk magnetic probes such as magnetometry and local magnetic probes such as .
Stereotactic radiosurgery (SRS) is a standard of care for many patients with brain metastases. To optimize post-SRS surveillance, this study aimed to validate a previously published nomogram predicting post-SRS intracranial progression (IP). We identified consecutive patients completing an initial course of SRS across two institutions between July 2017 and December 2020. Patients were classified as low- or high-risk for post-SRS IP per a previously published nomogram. Overall survival (OS) and freedom from IP (FFIP) were assessed via the Kaplan–Meier method. Assessment of parameters impacting FFIP was performed with univariable and multivariable Cox proportional hazard models. Among 890 patients, median follow-up was 9.8 months (95% CI 9.1–11.2 months). In total, 47% had NSCLC primary tumors, and 47% had oligometastatic disease (defined as ≤5 metastastic foci) at the time of SRS. Per the IP nomogram, 53% of patients were deemed high-risk. For low- and high-risk patients, median FFIP was 13.9 months (95% CI 11.1–17.1 months) and 7.6 months (95% CI 6.4–9.3 months), respectively, and FFIP was superior in low-risk patients (p < 0.0001). This large multisite BM cohort supports the use of an IP nomogram as a quick and simple means of stratifying patients into low- and high-risk groups for post-SRS IP.